MOUNTAIN VIEW, Calif.,
May 10, 2016 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or
the "Company") today announced that it intends to issue a press
release reporting financial results for the first quarter of fiscal
2016, as planned, immediately following the close of market on
Wednesday, May 11, 2016.
However, following the announcement on May 10, 2016, of Grupo Ferrer Internacional SA's
proposed acquisition of Alexza, Alexza has elected not to conduct a
conference call to discuss the quarterly financial results.
The call was previously scheduled for May 11, 2016 at 5:00 p.m.
Eastern Time.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions.
Alexza's products and development pipeline are based on the
Staccato® system, a hand-held inhaler designed to
deliver a pure drug aerosol to the deep lung, providing rapid
systemic delivery and therapeutic onset, in a simple, non-invasive
manner. Active pipeline product candidates include AZ-002
(Staccato alprazolam) for the management of epilepsy in
patients with acute repetitive seizures and AZ-007 (Staccato
zaleplon) for the treatment of patients with middle of the night
insomnia.
ADASUVE® is Alexza's first commercial product.
ADASUVE is approved for marketing in 42 countries and has been
submitted for approval in seven additional countries. ADASUVE
has been launched and is currently available in 21 countries.
Grupo Ferrer Internacional SA ("Ferrer") is Alexza's commercial
partner for ADASUVE in Europe,
Latin America, the Commonwealth of
Independent States countries, the Middle
East and North Africa
countries, Korea, the Philippines
and Thailand.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information about Alexza, the Staccato system technology or
the Company's development programs, please visit
www.alexza.com.
Safe Harbor Statement
Some statements in this
release may be "forward-looking statements" for the purposes of the
Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by words such as
"believe," "expect," "anticipate," "plan," "potential," "continue"
or similar expressions. Such statements are subject to certain
risks and uncertainties, including the ability of the parties to
complete the proposed acquisition of Alexza by Ferrer, the
likelihood that the minimum number of Alexza shares are tendered in
the offer related thereto, all closing conditions are satisfied and
Alexza's ability to secure additional funding to continue its
operations through the proposed closing. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Alexza's Annual Report on Form 10-K for the year
ended December 31, 2015 as updated
from time to time in Alexza's filings with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and Alexza undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-to-cancel-2016-first-quarter-financial-results-earnings-call-300265713.html
SOURCE Alexza Pharmaceuticals, Inc.